


EMBARGO, November 1st, 2017

When two wrongs make a right: Artificial CRISPR gene disruptions could rescue genetic disease



Defective DNA repair mechanisms can lead to diseases like Fanconi anemia. Utilizing a concept called “synthetic viability”, researchers at CeMM, in international collaboration, found additional gene disruptions that rescue the phenotype of this disease in cell culture and identified the responsible protein complex. The study, published in Nature Communications, intriguingly demonstrates the potential of synthetic viability screens to identify genetic interactions rescuing cells with defects in the DNA damage response.

Sunlight, cellular metabolism or simply faulty DNA replication: DNA damage occurs tens of thousands of times per day in every cell of the body. Hence, a whole arsenal of molecular

machineries stand by to repair various forms of damage and maintain cellular function. If those repair mechanisms fail, it can lead to serious diseases, as in the case of the Fanconi anemia pathway: named after the disease, its failure leads to impaired repair of DNA interstrand crosslink damage.

The research group of Joanna Loizou at CeMM, in international collaboration, showed with a so-called “synthetic viability” screen that cells with defects in the Fanconi anemia pathway can be rescued by introducing additional genetic defects, targeting genes of the BLM helicase complex. The study was published in Nature Communications (DOI: 10.1038/s41467-017-01439-x).

Using CRISPR/Cas9, the scientists produced a library of viruses able to disrupt almost all of the genes in the human genome individually. Millions of cells with Fanconi anemia defect were infected with those viruses, introducing a single additional gene defect in each cell. Subsequently, DNA interstrand crosslink damage was generated – the kind of DNA damage that should kill the diseased cells. With a high throughput assay, the researchers searched for cells that survived better after disrupting additional genes and found that upon loss of a functional BLM helicase complex, cellular survival of Fanconi anemia cells was increased and the cells behaved more like healthy ones.

This work demonstrates that genome-wide CRISPR/Cas9 screens are suitable to identify genetic “synthetic viable” interaction partners that increase the survival of cells with defective DNA damage repair mechanisms. Above that, the now published study clearly shows that the loss of both components (BLM & Fanconi anemia pathway) is less detrimental for cells than a deficiency of only the Fanconi anemia pathway – an important contribution to the elucidation of this rare genetic disease.

Publication

Martin Moder*, Georgia Velimezi*, Michel Owusu, Abdelghani Mazouzi, Marc Wiedner, Joana Ferreira da Silva, Lydia Robinson-Garcia, Fiorella Schischlik, Rastislav Slavkovsky, Robert Kralovics, Michael Schuster, Christoph Bock, Trey Ideker, Stephen P. Jackson, Jörg Menche and Joanna I. Loizou. Parallel genome-wide screens identify synthetic viable interactions between the BLM helicase complex and Fanconi anemia. Nature Communications, November 1st, 2017. DOI: 10.1038/s41467-017-01439-x.

Funding

This study was supported by the European Molecular Biology Organization (EMBO) and the Austrian Science Fund (FWF).

Joanna Loizou received her Ph.D. at the University of Manchester and Sussex with Keith Caldecott, and carried out post-doctoral research at the International Agency for Research on Cancer, Lyon, France with Zhao-Qi Wang and Zdenko Herceg and later at the London Research Institute, CRUK, England with Axel Behrens. She joined CeMM in 2011.

<http://cemm.at/research/groups/joanna-i-loizou-group/>

The mission of **CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences** is to achieve maximum scientific innovation in molecular medicine to improve healthcare. At CeMM, an international and creative team of scientists and medical doctors pursues free minded basic life science research in a large and vibrant hospital environment of outstanding medical tradition and practice. CeMM's research is based on post-genomic technologies and focuses on societally important diseases, such as immune disorders and infections, cancer and metabolic disorders. CeMM operates in a unique mode of super-cooperation, connecting biology with medicine, experiments with computation, discovery with translation, and science with society and the arts. The goal of CeMM is to pioneer the science that nurtures the precise, personalized, predictive and preventive medicine of the future. CeMM trains a modern blend of biomedical scientists and is located at the campus of the General Hospital and the Medical University of Vienna. www.cemm.at

Contact Details

Eva Schweng, MAS

Public Relations Manager

CeMM

Research Center for Molecular Medicine
of the Austrian Academy of Sciences

Lazarettgasse 14, AKH BT 25.3

1090 Vienna, Austria

Phone +43-1/40160-70 051

Fax +43-1/40160-970 000

eschweng@cemm.oeaw.ac.at

www.cemm.at
